Go Back
  • Posted by: Katherine Lee on Monday, January 28 2013 05:30 PM | Comments (7)

    HealthSpotThe US spends an annual $8,233 per person on healthcare, a figure that represents more than 2.5 times what comparatively developed nations spend. By a significant margin, the US spends the most on healthcare of any country in the world, a massive 17.6% of national GDP. *

    In the face of this, costs only continue to rise, and the 2011 National Scorecard on US Health System Performance suggests that healthcare access is still constrained by cost and a weak national primary care foundation. Primary care is the most cost-efficient form of medical care, many times cheaper than an urgent care visit.

    HealthSpot is a start-up that’s thinking outside of the traditional doctor’s office, aiming to assuage access issues by providing tiny, portable health clinics that offer patients a comprehensive primary care visit for $60-80 per visit.

    Their offering consists of a 10-foot mini-clinic equipped with dashboard screen, a chair, and medical tools you would expect to find in a primary care facility. A certified medical assistant is there to help patients check in, and a physician guides the patient through basic diagnostics via a graphic interface.

    Patients can visit for a variety of conditions usually treated in primary or urgent care settings, from a cold or flu or minor illnesses, to allergies, infections, and more. HealthSpot is working on finding ways to secure coverage for telemedicine and e-prescriptions, and they plan to place these tiny clinics conveniently, near highly frequented places like your local pharmacy, where you can be treated and walk right out to pick up your prescription.

    What do you think about this tiny, portable health clinic? Would you visit?

    Katherine Lee is Senior Creative Manager, Science Writer for InterbrandHealth.

    *OECD Health Data 2012

    Post a comment

  • Posted by: Jonathan Lanznar on Thursday, June 28 2012 04:55 PM | Comments (1)
    Corporate Citizenship & Healthcare

     

    Over the past few years, we have seen many non-healthcare organizations focusing more and more on health. Companies including Bosch, Philips, Siemens, Microsoft and GE, to name just a few, have done significant work in healthcare related areas and earned a lot of positive credit. Healthcare businesses are leading ambitious drives in corporate citizenship as well, but attention for these campaigns seems minimal. Did you know that the same company that created VIOXX also helped cure river blindness in developing nations?

    So the questions we've been asking ourselves are: Why are healthcare businesses, whose primary focus and goal are advancing care, getting less credit for their work in healthcare than other businesses? And how can they amplify this message effectively?

    The answers to these questions are not all that simple. Corporate citizenship used to center mainly on sustainability and green initiatives, but health initiatives have gained increasing importance. As we’ve been saying: If five years ago “green was the new black,” then health is now the new green.

    Given this shifting focus, the health and life sciences industry is faced with a unique business opportunity and some questions. At the precise time that corporations across other industries are placing greater emphasis on corporate citizenship efforts, how does corporate citizenship play a role in this unique field? What role does it have in brand strategies and, ultimately, in driving business goals?

    I imagine that when most people think about the healthcare industry, corporate citizenship is rarely a subject that rises to the top. Instead, what comes to mind are typical issues that have continued to demonize the industry over the past few decades—pricing strategies, limited access to care, rising costs, and ubiquitous lawsuits, to name a few. No one seems to be talking about the incredible advances in cancer therapy or initiatives to eliminate preventable disease across the world. The result: work that is essentially good for people and society is most often viewed through only a negative lens.

    It seems as though health and life sciences companies are missing a large opportunity. So why is it that health and life sciences companies are not leveraging their brands to help mitigate some of this risk and negative perception?

    It’s not that healthcare companies haven’t been doing good work all along— it’s that they haven’t been able to effectively communicate the good work that they do. The reason is that product brands have historically dominated the pharma, biotech, and medical device industries, and product brands don't have the ability to communicate the positive impact of corporate citizenship. A product brand can’t take credit for creating drastic advances in cancer care— but a corporate brand can. A product brand can’t take credit for corporate citizenship activities— but a corporate brand can.

    At InterbrandHealth we’ve been focusing on the increasing role of the corporate brand in healthcare— see Wes Wilkes’ white paper “Vital Times: The Changing Role of Brand in the Health and Life Sciences Industry.” We believe the health and life sciences industry is experiencing dramatic value-driven transformational change, and along with that comes the need to shift the focus from product brands to corporate brands.

    As health and life sciences companies begin to emphasize the corporate brand over product brands, the commitment to corporate citizenship can finally benefit the brand and business.

    While we’re not so enthusiastic as to assume that this shift will make people think only positively about the industry, we do believe this will allow companies to at least get credit for the good that they do. Health and life sciences companies will always have to deal with risk, for example, product failures and black box warnings, but being a good corporate citizen— and letting the world know about it— can potentially help mitigate some of the risks that inevitably will come by demonstrating company cultures focused on helping society and developing innovative solutions to global health problems.

    Ultimately, with this increased focus on corporate citizenship and the growing visibility of corporate brands, there’s one question left to ask: Is your current corporate brand strong enough to support the increased presence and visibility?

    Jonathan Lanznar is a Strategy Consultant for InterbrandHealth.

    Post a comment

  • Posted by: Jyotsna Kini on Monday, April 9 2012 02:25 PM | Comments (0)

    On March 27th, the FDA approved Omontys (peginesatide), a drug used to treat anemia in adult dialysis patients who have chronic kidney disease (CKD). Omontys represents the first innovation in two decades – 20 years where the only option for CKD patients has been Amgen's Epogen. InterbrandHealth worked with Affymax and Takeda Pharmaceuticals to develop a brand name that would allow peginesatide to breathe fresh air into an older category riddled with monopoly.

    The market is excited to have a new treatment option and Omontys is poised to transform the world of anemia in CKD – it is slated to generate as much as $700 million in peak sales by 2017.

    Congratulations to Affymax and Takeda on this significant FDA approval!

    Jyotsna Kini is a Creative Director with InterbrandHealth in New York.

    Post a comment

  • Posted by: Melody Wolff on Tuesday, April 3 2012 12:48 PM | Comments (0)

    There has been a dark cloud looming over some of big pharma's giants as blockbuster drugs come off patent. According to Healthcare Finance News, big pharma is going to face major headwinds this year due to the upcoming patent expirations of the following blockbusters — Seroquol, Lexapro, Plavix, Singular and Actos.

    There is, however, a way for pharmaceutical companies to harness flux and overcome the loss of their cash cow’s patent. A different brand strategy can provide just the life line needed. Pharmaceutical companies should consider their corporate brand at the heart of the their overall brand strategy. Corporate brand becomes the solution for differentiating in a crowded marketplace with similar and, more importantly, cheaper generic drugs.

    Brand is playing a larger role in purchase decisions within the healthcare industry. In an environment where the marketing focus and budget were traditionally dedicated to the individual product brand, industry turbulence, including patent expiration, is creating a need for a different brand strategy in healthcare ... and thus we see the rise of the healthcare corporate brand.

    More and more we are seeing that consumers are willing to pay a premium for their healthcare. People pay a premium for designer spin and yoga classes that promise health and well-being, so why wouldn’t they buy upward when it comes to the pharmaceutical drugs that they put into their body and on which they rely on to keep them healthy and in often cases alive? I know I would certainly prefer to take a drug made by Pfizer, Johnson & Johnson or AstraZeneca to a possibly unsafe, generic drug.

    Healthcare branding and pharmaceutical branding are becoming no different than luxury goods branding — although the role that brand plays in healthcare is still light years away from that in the luxury goods market, the shift is happening and big pharma needs to pay attention and adjust their brand strategy.

    Corporate brand is a branding strategy that is becoming more important in emerging markets. The strong corporate brand conveys credibility and reliability to all stakeholders: To physicians and patients, the message is equivalence, efficacy and safety. To the pharmacist, the message is reliability and ability to manufacture and deliver the product. Generic drugs just don't have the same reputation as their brand name counterparts and are not able to communicate the messages that influence purchase decision in emerging markets.

    From a healthcare branding-consultancy perspective, InterbrandHealth takes an in depth look at the role that brand plays in the pharmaceutical and even broader healthcare industries, with the paper “Vital Times: The Changing Role of Brand in the Health and Life Sciences industries.”

    There is no doubt that 2012 will be a difficult time for big pharma, but a change in brand strategy could be just the prescription needed to sustain and outlive the turbulence this year is sure to bring.

    Melody Wolff is a Manager at InterbrandHealth

    Post a comment

  • Posted by: Interbrand on Thursday, March 22 2012 11:08 AM | Comments (0)

    Jez Frampton

    Welcome to part 2 of this Demand and Desire special, where Interbrand’s Global CEO, Jez Frampton, joins Global Chief Communications Officer, Karen Burke, in examining what 2012 has in store for these eight sectors:

    • Financial
    • Hospitality
    • Food & Beverage
    • Healthcare
    • Luxury
    • Telecommunications
    • Media
    • Retail

     

    download mp3

    Subscribe to Demand and Desire:

    add to iTunes add to zune add to podnova add to newsgator add to netvibes add to pageflakes add to yahoo add to google

     

    Post a comment

  1. 1
  2. 2
  3. Next page